News | Endovascular Aortic Repair | October 26, 2022

UH Harrington Heart and Vascular Institute Performs First TRIOMPHE Study Case in Northeast Ohio

Clinical study evaluates treatment for endovascular aortic arch repair 

Clinical study evaluates treatment for endovascular aortic arch repair

October 26, 2022 —  Thousands of people have new hope for treatment of thoracic aortic arch disease and University Hospitals (UH) Harrington Heart & Vascular Institute is at the forefront of studying the safety and efficacy of this new procedure. A surgical team from UH is the first in Northeast Ohio to implant the NEXUS Aortic Arch Stent Graft System into a patient as part of the TRIOMPHE IDE Study

The TRIOMPHE Study is a multi-arm, multi-center, non-randomized, prospective, clinical study to evaluate the safety and effectiveness of the NEXUS system in treating problems of the thoracic aorta that involve the aortic arch -- the segment of the aorta that helps distribute blood to the head and upper extremities. The study will enroll 100 patients. UH Harrington Heart & Vascular Institute is one of 30 participating sites in the United States and New Zealand. 

“Treating patients with thoracic aortic arch disease presents many challenges,” said Jae Cho, MD, vascular surgeon, co-director of the Aortic Disease Center at UH Harrington Heart & Vascular Institute, and the Brenda and Marshall Brown Master Clinician in Vascular Innovation. “As leaders in the fields of cardiac and vascular surgery, we knew this was an important study in which our participation could make a great difference for patients. This system has the potential to create a better experience for patients and improve outcomes.” 

“We are so pleased to be able to provide a treatment for our patients with aortic arch and descending aortic pathologies, including arch aneurysms and chronic dissections, that doesn’t involve a big open chest surgery,” said Yakov Elgudin, MD, PhD, cardiac surgeon at UH Harrington Heart & Vascular Institute. “Minimally invasive procedures improve the patient experience because there is generally less pain and a shorter recovery time compared to procedures where we need to open their breastbone.” 

More than 120,000 patients suffer thoracic aortic arch disease every year in the USA and Europe, with only about 25 percent being diagnosed or treated. This disease causes a weakened area in the aorta and can lead to serious health risks. The weak area can cause a bulge in the portion of the aorta closest to the heart which can burst or rupture and lead to severe life-threatening internal bleeding. This portion of the aorta can also experience problems like ulcers, tearing, and leaking. 

The aortic arch presents complexities for repair because of its size, shape and location. Despite major advances, open chest surgical aortic arch repair has relatively high death and complication rates, and for these reasons, many patients aren’t eligible. Historically, even minimally invasive repair to the aortic arch has proven difficult.  

The NEXUS Aortic Arch Stent Graft System was specifically engineered for minimally invasive total arch repair to overcome the challenges of the aortic arch anatomy. NEXUS is delivered by traveling through a patient’s vascular system using fluoroscopic guidance (x-ray pictures), starting with a small incision or needle puncture near the groin. This delivery method is called an endovascular approach.  

NEXUS is designed to make a minimally invasive repair possible for more patients while possibly reducing the risks of surgery. This could correlate to a reduction in both procedure time and post-operative hospital stay, as well as potentially more optimal outcomes. 

“Improving the lives of our patients is what’s most important. This is why we participate in research studying the future of cardiovascular treatments and we’re hopeful to discover more successful therapies for challenging cases,” said Dr. Cho. 

For more information: www.uhhospitals.org 

 

Related content: 

Nexus Arch Branch Stent Graft System Shows Positive Mid-term Results 

VIVA 2019 Late-breaking Clinical Trials


Related Content

News | Endovascular Aortic Repair

June 19, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home June 19, 2024
Home
News | Endovascular Aortic Repair

October 30, 2023 — -egnite, Inc., a leading cardiovascular digital health company, announced today that novel research ...

Home October 30, 2023
Home
News | Endovascular Aortic Repair

December 5, 2022 — Imagen Technologies, Inc. announced the U.S. Food and Drug Administration's 510(k) clearance of the ...

Home December 05, 2022
Home
News | Endovascular Aortic Repair

March 22, 2022 – A retrospective evaluation of 600 fenestrated-branched endovascular aortic repairs for the treatment of ...

Home March 22, 2022
Home
News | Endovascular Aortic Repair

February 18, 2022 – Front Line Medical Technologies, Inc. today announced the expanded availability and distribution of ...

Home February 18, 2022
Home
News | Endovascular Aortic Repair

May 12, 2021 — Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a ...

Home May 12, 2021
Home
News | Endovascular Aortic Repair

February 23, 2021 — Medtronic has voluntarily issued a global recall of unused Medtronic Valiant Navion thoracic stent ...

Home February 23, 2021
Home
News | Endovascular Aortic Repair

January 31, 2020 – The Society for Vascular Surgery (SVS) and Society of Thoracic Surgeons (STS) released new reporting ...

Home January 31, 2020
Home
News | Endovascular Aortic Repair

January 29, 2020 – The presence of a blood clot on the wall of the aorta in people with abdominal aortic aneurysms (AAA) ...

Home January 29, 2020
Home
News | Endovascular Aortic Repair

November 7, 2019 — The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for ...

Home November 11, 2019
Home
Subscribe Now